Gujarat Themis Biosyn Limited (NSE:GUJTHEM)
260.60
+9.29 (3.70%)
Apr 6, 2026, 3:29 PM IST
Gujarat Themis Biosyn Revenue
Gujarat Themis Biosyn had revenue of 433.68M INR in the quarter ending December 31, 2025, with 9.74% growth. This brings the company's revenue in the last twelve months to 1.59B, up 2.74% year-over-year. In the fiscal year ending March 31, 2025, Gujarat Themis Biosyn had annual revenue of 1.51B, down -11.20%.
Revenue (ttm)
1.59B
Revenue Growth
+2.74%
P/S Ratio
17.85
Revenue / Employee
7.21M
Employees
221
Market Cap
28.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.51B | -190.22M | -11.20% |
| Mar 31, 2024 | 1.70B | 214.37M | 14.45% |
| Mar 31, 2023 | 1.48B | 335.31M | 29.19% |
| Mar 31, 2022 | 1.15B | 242.91M | 26.82% |
| Mar 31, 2021 | 905.63M | 54.38M | 6.39% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aarti Pharmalabs | 18.01B |
| Indoco Remedies | 17.60B |
| Innova Captab | 14.97B |
| Solara Active Pharma Sciences | 12.55B |
| Windlas Biotech | 8.68B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 6.74B |
| Ind-Swift Laboratories | 5.94B |
Gujarat Themis Biosyn News
- 6 months ago - Gujarat Themis Biosyn begins commercial production after major capacity expansion at Vapi facility - Business Upturn
- 11 months ago - Gujarat Themis Biosyn starts commercial production at new API plant in Vapi, Gujarat - Business Upturn
- 1 year ago - Themis Medicare shares surge nearly 2% following amalgamation announcement - Business Upturn